Cabozantinib plus nivolumab and ipilimumab delays progression in kidney cancer
Preliminary results from the COSMIC-313 clinical trial have ben released. [...]
Genetic biomarkers for the survival of kidney cancer patients
Previously, researchers found some genes that helped identify which patients [...]
Nivolumab plus ipilimumab and live bacteria supplements in advanced kidney cancer
Researchers are interested in the bacteria in our gut (the [...]
Ipilimumab plus nivolumab combination approved for use on the NHS
The National Institute for Health and Care Excellence (NICE) has [...]
First-line nivolumab plus ipilimumab in kidney cancer patients without nephrectomy
A recent post hoc analysis of the CheckMate 214 trial [...]
Real world incidence of immune-related side effects to ipilimumab/nivolumab in kidney cancer patients
A recent study published in Journal of Clinical Medicine this [...]
ESMO 2021: First-line nivolumab/ipilimumab – probability of survival in 5-year follow-up
The use of two medicines together (combination therapies) for previously [...]
ESMO 2021: Alternative treatment schedule for ipilimumab plus nivolumab in first-line treatment of advanced RCC (PRISM)
Ipilimumab plus nivolumab is a standard first-line treatment for patients [...]
ASCO 2021: Gut microbiome boosts nivolumab/ipilimumab activity
Recent evidence suggests that the bacteria in the gut (the [...]
ASCO 2021: Nivolumab plus ipilimumab for the treatment of kidney cancer brain metastases
Brain metastases resulting from the spread of renal cell carcinoma [...]
